2022-04-20

Elusys Invited to Present LAV-BASTA-48 Anthrax Vaccine at the Annual Defense Threat Reduction Agency (DTRA) Chemical and Biological Science & Technology Annual Conference Live Attenuated Single-Dose Spore-Based MDR-Anthrax Vaccine elicits protective immunity for...

2022-04-27

Elusys Executes Initial Procurement Contract to Deliver ANTHIM® to the Canadian Government New contract marks the first international sale of ANTHIM® PARSIPPANY, N.J., April 27, 2022 – Today Elusys Therapeutics annoucned it has finalized a contract with the Canadian...

2020-08-12

ELUSYS THERAPEUTICS RECEIVES HEALTH CANADA APPROVAL FOR ANTHIM® FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, AUGUST 12, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for...

2020-10-08

OBILTOXAXIMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF INHALATION ANTHRAX European Commission Decision Anticipated in November 2020 PARSIPPANY, NJ, OCTOBER 8, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the Committee for Medicinal...

2020-12-02

OBILTOXAXIMAB RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, DECEMBER 2, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company’s...

2022-01-31

ELUSYS THERAPEUTICS FINALIZES HHS CONTRACT TO DELIVER ANTHIM®, ITS TREATMENT FOR INHALATION ANTHRAX, TO THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first...